Navigation Links
Huge Potential in Biosimilars if Generic Providers Overcome Regulatory Hurdles
Date:4/22/2008

NEW YORK, April 22 /PRNewswire/ -- Some of the biggest-selling biologics developed during the boom years in biotech of the 1980's, including human growth hormone (hGH) and insulin, have lost patent protection in the U.S. in 2007 or will shortly, and they represent a market of $40 billion. This opens up a huge potential market for biosimilars, if regulatory hurdles can be overcome, according to a new report by Kalorama Information, Biogenerics: the World Market for Biosimilars.

Worldwide interest in biosimilars is gaining momentum and is expected to reach $5.8 billion by 2012. But first such stumbling blocks as safety, access to innovators' key intermediates, process controls, availability and access to bulk materials, specifically designed and adapted analytical procedures and validation studies must be addressed. Also, biosimilars cannot currently be marketed in the U.S. because there is no pathway for them to reach the market.

"Right now, there is limited competition in biosimilars due to the complicated regulatory process and the high costs," notes Mary Anne Crandall, senior analyst for Kalorama. "But this won't last forever, and in fact in the near-term we should see some technological changes and political shifts that will fuel the market."

Biosimilars have been selling outside of the U.S. for years, creating a small existing market. As the industry is allowed in the U.S., which Kalorama predicts will happen in a serious way by 2009, it will grow exponentially. Growth will likely occur around a few big biopharmaceuticals at first.

Kalorama Information's report Biogenerics: the World Market for Biosimilars identifies the biopharmaceuticals that have lost patent protection and are likely to be the first products attempted by generic companies. Current and future trends, market size and projections are also provided. The report can be purchased directly from Kalorama Information by visiting

SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Gladstone scientists uncover potential mechanism of memory loss in Alzheimers disease
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Pharmaceutical Product Launch: Commercially Focused R&D Increases Drugs Market Potential
6. Agendia Acquires Rights to the Discovery of a Major Drug Resistance Mechanism in Breast Cancer Potentially Leading to a Herceptin(R) Sensitivity Test
7. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
8. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
9. Discovery of creator gene for cerebral cortex points to potential stem cell treatments
10. Research Using Thermo Fisher Scientific RNA-Interference Technology Unveils Potential New Targets for HIV Drugs
11. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... 2014 SoundConnect , an ... is proud to announce the addition of Adobe ... Connect’s elearning tools to quickly deploy and manage ... training tools for desktop and mobile learning solutions. ... the perfect online training solution, enabling organizations to ...
(Date:7/30/2014)... , July 30, 2014 Regulus ... biopharmaceutical company leading the discovery and development of innovative ... financial results and highlights for the quarter ended June ... U.S. financial markets close. Regulus will ... 6, 2014, at 5:00 pm Eastern Daylight Time to ...
(Date:7/30/2014)... July 30, 2014 A study presented ... safety and efficacy of CSL Behring,s C1 Inhibitor ... transplants in highly sensitized patients. C1-INH is a ... complement system. The study shows that ... in the levels of complement components 3 and ...
(Date:7/30/2014)... 30, 2014 Selexis SA , ... drug discovery and mammalian cell line development, announced today ... ™ will be presented at the 10th Annual ... September 8 – 10, 2014 at the Double Tree ... The following abstract will be presented during an oral ...
Breaking Biology Technology:SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 2Study Suggests C1-INH May Aid in Prevention of Antibody-Mediated Rejection Following Kidney Transplant 3Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3
... County Representatives Unveil State-of-the-Art Facility ... ... Officials from Novavax,Inc. (Nasdaq: NVAX ), the State ... new state-of-the-art vaccine production,facility at the company,s headquarters in Rockville, ...
... Total Revenues of $62.0 Million, Up 55 Percent over First Quarter ... 2007, - First ... Before Non-Cash Charges of $1.13 per Basic Share, ... per Diluted Share, SILVER SPRING, Md., May 1 United Therapeutics,Corporation (Nasdaq: UTHR ) ...
... Strategic Transactions Increase EUSA,s Focus on Late-Stage and Marketed ... ... Products, DOYLESTOWN, Pennsylvania and OXFORD, England, May 1 ,EUSA ... pain control and critical care, today announced that,it has divested ...
Cached Biology Technology:Novavax Opens Its First U.S. Vaccine Plant 2Novavax Opens Its First U.S. Vaccine Plant 3Novavax Opens Its First U.S. Vaccine Plant 4United Therapeutics Reports First Quarter 2008 Financial Results 2United Therapeutics Reports First Quarter 2008 Financial Results 3United Therapeutics Reports First Quarter 2008 Financial Results 4United Therapeutics Reports First Quarter 2008 Financial Results 5United Therapeutics Reports First Quarter 2008 Financial Results 6United Therapeutics Reports First Quarter 2008 Financial Results 7EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 2EUSA Pharma Divests Monoclonal Antibody Research Business and Early-Stage Oncology Product 3
(Date:7/30/2014)... paving the way for a breakthrough that may ... exposed to poisonous chemicalsparticularly those in pesticides and ... current issue of the journal ChemBioChem ... compounds commonly used in pesticides and warfare agents. ... of Engineering Associate Professor of Chemical and Biological ...
(Date:7/30/2014)... studying the potential effects of climate change on ... on the wrong factors, according to a new ... Conservation Society, University of Queensland, and other organizations. ... science is missing the point when it comes ... of climate change scientists focus on the "direct" ...
(Date:7/30/2014)... pleased to announce its new relationship with the International ... CINP will partner to publish International Journal of ... journal. , Alan Frazer, Editor-in-Chief of IJNP ... of OUP will further facilitate the goal for the ... leading journals within neuropsychopharmacology. The conversion of the ...
Breaking Biology News(10 mins):Engineering a protein to prevent brain damage from toxic agents 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2OUP to partner with the International College of Neuropsychopharmacology 2
... a research team from the National Institute of Standards ... has shown how to detect and monitor the tiny ... of an atomic force microscope probe, and in so ... of the instruments measurements under ambient conditions. Their recently ...
... have learned to manipulate the proportion of females and ... mapped the entire genome of a bacterium that infects ... published in PNAS, reveal extremely high frequencies of gene ... it is hoped that it will be possible to ...
... DC, March 25, 2009 - Critically endangered hawksbill turtles ... the Dominican Republic after a powerful government campaign cracked ... 99 percent of these souvenirs have been withdrawn or ... A 2006 survey carried out by TRAFFIC found ...
Cached Biology News:Making a point: Picoscale stability in a room-temperature AFM 2Gene exchange common among sex-manipulating bacteria 2Turtles no longer turned into souvenirs 2
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient...
Many mammalian cell types and experimental situations create challenges for standard transfection experiments. The ViraPower Lentiviral Expression System overcomes these challenges with efficient vir...
Src cDNA Expression Kit (wild type)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: